A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes
Megadott ok: The study is withdrawn due to strategic reasons.
Key facts
- Where
- Conyers, Cumberland, Gurnee, Houston, Lampasas, Little Rock, Longwood, Maumee, Miami, Nashville, Oak Lawn, Ocoee, Pembroke Pines, San Antonio, San Diego, Sherman, Spring Valley, Walnut Creek és Wilmington, Egyesült ÁllamokSee the 21 sites
- Phase
- 2. fázis
Where in Egyesült Államok
- Hope Clin Res & WellnessConyers, Egyesült ÁllamokNo longer taking part
- Clinical Res CollaborativeCumberland, Egyesült ÁllamokNo longer taking part
- Elevate Clinical ResearchGurnee, Egyesült ÁllamokNo longer taking part
- The Endocrine CenterHouston, Egyesült ÁllamokNo longer taking part
- Radiance Clinical ResearchLampasas, Egyesült ÁllamokNo longer taking part
- Arkansas Clinical ResearchLittle Rock, Egyesült ÁllamokNo longer taking part
- Future Medical ResearchLongwood, Egyesült ÁllamokNo longer taking part
- Advanced Medical Research - MaumeeMaumee, Egyesült ÁllamokNo longer taking part
- Clinical Site Partners Kendall Flourish ResearchMiami, Egyesült ÁllamokNo longer taking part
- New Horizon Research CenterMiami, Egyesült ÁllamokNo longer taking part
- Clinical Research AssociatesNashville, Egyesült ÁllamokNo longer taking part
- Accellacare of Duly Oak LawnOak Lawn, Egyesült ÁllamokNo longer taking part
- West Orange EndocrinologyOcoee, Egyesült ÁllamokNo longer taking part
- American Research Centers of FloridaPembroke Pines, Egyesült ÁllamokNo longer taking part
- Center for Diab,Obes & MetabPembroke Pines, Egyesült ÁllamokNo longer taking part
- Quality Research IncSan Antonio, Egyesült ÁllamokNo longer taking part
- Paradigm Clinical ResearchSan Diego, Egyesült ÁllamokNo longer taking part
- Medrasa Clinical ResearchSherman, Egyesült ÁllamokNo longer taking part
- Encompass Clinical Research_Spring ValleySpring Valley, Egyesült ÁllamokNo longer taking part
- Diablo Clinical Research, Inc.Walnut Creek, Egyesült ÁllamokNo longer taking part
- KDCILM, LLC & Accellacare US, Inc.Wilmington, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07357740
- Record updated
- 2026. július 9.
- Original description
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.Read full original descriptionShow less
A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes
This study is being done to look at how well a study medicine called CagriSema helps people with diabetes lower their blood sugar. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. The study will last for about 38 weeks.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18-64 years (both inclusive) at the time of signing the informed consent; Diagnosed with type 2 diabetes mellitus greater than or equal to (>=) 180 days before screening; Glycated haemoglobin (HbA1c) 7.0-10.5 percent (%) (53-91 [millimoles per mole] mmol/mol) (both inclusive) as determined by the central laboratory at screening; Stable daily dose >= 90 days before screening of metformin at effective or maximum tolerated dose as judged by the investigator; Body mass index (BMI) between 25.0 and 39.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening.
Exclusion: Treatment with any anti-diabetic or anti-obesity medication (irrespective of indication) other than stated in the inclusion criteria within 90 days before screening; Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation; Previous exposure to CagriSema in a clinical study; Renal impairment with estimated Glomerular Filtration Rate (eGFR) < 30 millilitre per minute per 1.73 square metre (mL/min/1.73 m\^2) as determined by the central laboratory at screening.